Insmed (NASDAQ:INSM) Shares Gap Down – Time to Sell?

Insmed, Inc. (NASDAQ:INSM) gapped down prior to trading on Thursday . The stock had previously closed at $137.09, but opened at $116.91. Insmed shares last traded at $117.1150, with a volume of 1,473,405 shares changing hands.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Q1 results beat consensus modestly: EPS of ($0.76) topped estimates and total revenue of ~$306M slightly exceeded Street expectations; BRINSUPRI Q1 sales were $207.9M (wide QoQ growth) and management reiterated a 2026 BRINSUPRI revenue target of at least $1B and ARIKAYCE guidance of $450–$470M — evidence of strong commercial traction for core products. Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Clinical/readout progress supports longer-term growth: the Phase 3b ENCORE study for ARIKAYCE met its primary and multiplicity-controlled secondary culture-conversion endpoints, and Insmed is targeting an ARIKAYCE label expansion in H1 2027 — a successful label expansion could broaden use and lift future revenue. Insmed reiterates BRINSUPRI at least $1B 2026 revenue target while targeting ARIKAYCE label expansion in H1 2027
• Positive Sentiment: Pipeline momentum: Insmed initiated the Phase 3 PALM-PAH study of TPIP in PAH patients in April 2026 — new late-stage programs diversify long-term upside beyond current product sales. Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Awareness campaign launched: Insmed partnered with Ty Pennington to raise recognition and diagnosis of bronchiectasis (may help long-term uptake of BRINSUPRI but is a gradual marketing play). Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
• Negative Sentiment: Guidance and mixed messaging pressured the stock: media/analyst coverage highlighted that management’s updated FY guidance/readthroughs were viewed as light versus some Street expectations (reported aggregate/total revenue commentary cited below-consensus figures), and some outlets framed the quarter as a miss — that disconnect between operational beats and perceived forward guidance shortfall likely triggered heavy selling. Insmed tanks on its most important launch; why analysts remain bullish
• Negative Sentiment: Conflicting coverage on the quarter (some outlets called it a revenue miss) added to volatility — that mixed narrative amplified the sell-off despite beats on EPS and product growth. Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Bank of America raised their target price on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Stifel Nicolaus raised their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Finally, Wells Fargo & Company lowered their price target on Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, March 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $213.23.

Insmed Price Performance

The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a market capitalization of $22.74 billion, a PE ratio of -16.44 and a beta of 0.89. The company’s fifty day simple moving average is $146.94 and its two-hundred day simple moving average is $165.89.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.21. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the prior year, the firm earned ($1.42) earnings per share. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, sell-side analysts predict that Insmed, Inc. will post -2.41 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the sale, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,361,604.45. This represents a 3.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 174,589 shares of company stock valued at $27,441,807. 2.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its position in Insmed by 13.1% during the first quarter. Parallel Advisors LLC now owns 2,291 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 266 shares during the last quarter. AlphaCentric Advisors LLC grew its position in Insmed by 16.9% during the first quarter. AlphaCentric Advisors LLC now owns 8,874 shares of the biopharmaceutical company’s stock valued at $1,451,000 after acquiring an additional 1,286 shares during the period. KBC Group NV increased its position in Insmed by 9.8% during the 1st quarter. KBC Group NV now owns 37,347 shares of the biopharmaceutical company’s stock worth $6,107,000 after purchasing an additional 3,334 shares in the last quarter. SEB Asset Management AB acquired a new stake in Insmed in the first quarter valued at approximately $27,075,000. Finally, Swiss National Bank boosted its stake in Insmed by 8.1% during the 1st quarter. Swiss National Bank now owns 625,912 shares of the biopharmaceutical company’s stock valued at $102,349,000 after acquiring an additional 46,800 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.